MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cmi.2022.04.009

Медицинская библиотека · Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022

Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial.

Ten Doesschate Thijs, van der Vaart Thomas W, Debisarun Priya A, Taks Esther, Moorlag Simone J C F M, Paternotte Nienke, Boersma Wim G, Kuiper Vincent P, Roukens Anna H E, Rijnders Bart J A, Voss Andreas, Veerman Karin M, Kerckhoffs Angele P M, Oever Jaap Ten, van Crevel Reinout, van Nieuwkoop Cees, Lalmohamed Arief, van de Wijgert Janneke H H M, Netea Mihai G, Bonten Marc J M, van Werkhoven Cornelis H

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

The COVID-19 pandemic increases healthcare worker (HCW) absenteeism. The bacillus Calmette-Guérin (BCG) vaccine may provide non-specific protection against respiratory infections through enhancement of trained immunity. We investigated the impact of BCG vaccination on HCW absenteeism during the COVID-19 pandemic.

METHODS

HCWs exposed to COVID-19 patients in nine Dutch hospitals were randomized to BCG vaccine or placebo in a 1:1 ratio, and followed for one year using a mobile phone application. The primary endpoint was the self-reported number of days of unplanned absenteeism for any reason. Secondary endpoints included documented COVID-19, acute respiratory symptoms or fever. This was an investigator-funded study, registered at ClinicalTrials.gov (NCT03987919).

RESULTS

In March/April 2020, 1511 HCWs were enrolled. The median duration of follow-up was 357 person-days (interquartile range [IQR], 351 to 361). Unplanned absenteeism for any reason was observed in 2.8% of planned working days in the BCG group and 2.7% in the placebo group (adjusted relative risk 0.94; 95% credible interval, 0.78-1.15). Cumulative incidences of documented COVID-19 were 14.2% in the BCG and 15.2% in the placebo group (adjusted hazard ratio (aHR) 0.94; 95% confidence interval (CI), 0.72-1.24). First episodes of self-reported acute respiratory symptoms or fever occurred in 490 (66.2%) and 443 (60.2%) participants, respectively (aHR: 1.13; 95% CI, 0.99-1.28). Thirty-one serious adverse events were reported (13 after BCG, 18 after placebo), none considered related to study medication.

CONCLUSIONS

During the COVID-19 pandemic, BCG-vaccination of HCW exposed to COVID-19 patients did not reduce unplanned absenteeism nor documented COVID-19.

Для цитирования: Ten Doesschate Thijs, van der Vaart Thomas W, Debisarun Priya A, Taks Esther, Moorlag Simone J C F M, Paternotte Nienke, Boersma Wim G, Kuiper Vincent P, Roukens Anna H E, Rijnders Bart J A, Voss Andreas, Veerman Karin M, Kerckhoffs Angele P M, Oever Jaap Ten, van Crevel Reinout, van Nieuwkoop Cees, Lalmohamed Arief, van de Wijgert Janneke H H M, Netea Mihai G, Bonten Marc J M, van Werkhoven Cornelis H. Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022. DOI: 10.1016/j.cmi.2022.04.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.